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both of these countries report cases of the disease
in their citizens who have been travelling within
their own countries. In 2003, 17 of the 18 clusters
reported in France would not have been detected
without internal reporting, and six of 14 clusters
in Italy would also have been missed [1]. In other
countries, such as Austria, data protection is often
a welcome justiﬁcation for impeding mandatory
reporting of all cases to EWGLINET. Fear of being
blamed as a ‘nestbeschmutzer’ (a person who
spoils his ⁄her own nest) is an additional obstacle
to addressing national problems at a European
level, with the result that relevant opportunities to
prevent avoidable disease are missed. The cases
of Legionnaires’ disease associated with travel in
Austria, both in foreigners and in Austrian citi-
zens, highlight the need for implementation of the
European guidelines [2], adapted to national
conditions, so that the appropriate measures can
be taken to control the risk of travel-associated
Legionnaires’ disease.
REFERENCES
1. Ricketts K, Joseph C, on behalf of the European Working
Group for Legionella Infections. Travel associated Legion-
naires’ disease in Europe: 2003. Euro Surveill 2004; 9: 5–6.
2. Members of the European Surveillance Scheme for Travel
Associated Legionnaires’ Disease and the European
Working Group for Legionella Infections. European guide-
lines for control and prevention of travel-associated Legionnaires’
disease. http://www.ewgli.org/public_info/publicinfo_
european_guidelines.asp.
3. Schmid D, Wewalka G, Allerberger F. Need for national
level outbreak control in Austria. Lancet 2004; 363: 2002.
RESEARCH NOTE
Clinical features and outcome of patients
with community-acquired Pseudomonas
aeruginosa bacteraemia
C.-I. Kang1, S.-H. Kim1, W. B. Park1,
K.-D. Lee1, H.-B. Kim1, E.-C. Kim2,3,
M.-D. Oh1,3 and K.-W. Choe1,3
Departments of 1Internal Medicine and 2Labor-
atory Medicine, Seoul National University
College of Medicine and 3Clinical Research
Institute, Seoul National University Hospital,
Seoul, Republic of Korea
ABSTRACT
Cases of community-acquired Pseudomonas aeru-
ginosa bacteraemia (n = 39) that occurred at a
tertiary-care hospital during a 5-year period were
analysed retrospectively. The commonest under-
lying diseases were solid tumour (41%) and
haematological malignancy (18%). Most (44%)
of the patients were neutropenic, and 39% had
septic shock at initial presentation. The 30-day
attributable mortality rate was 39%. Two pre-
viously healthy patients were identiﬁed with
fatal P. aeruginosa pneumonia with bacteraemia.
P. aeruginosa bacteraemia is a fatal infection that
should be considered in the differential diagnosis
of patients presenting from the community with
rapidly progressive sepsis.
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Pseudomonas aeruginosa is an important nosocomial
pathogen [1,2], and can be difﬁcult to treat because
of resistance to many antibiotics, including antibi-
otics used commonly in the community. Commu-
nity-acquired P. aeruginosa sepsis has been
reported in previously healthy patients [3,4], but
because the symptoms of bacteraemia are non-
speciﬁc, the initial antibiotic therapy is almost
always empirical, pending identiﬁcation of the
responsible pathogens [5]. It is therefore important
to determine the likelihood that P. aeruginosa is the
cause of a particular infection syndrome. Further-
more, there are limited data regarding community-
acquired bacteraemia caused by P. aeruginosa.
Thus, the present study investigated community-
acquired cases of P. aeruginosa bacteraemia that
presented at a tertiary-care hospital, in order to
determine the potential risk factors forP. aeruginosa
infection, and to examine the clinical features and
outcome.
Clinical microbiology laboratory and medical
records of individuals were reviewed from Janu-
ary 1998 to December 2002 at Seoul National
University Hospital (Seoul, Korea), a 1500-bed
tertiary-care university hospital and referral cen-
tre, to identify patients with clinically signiﬁcant
P. aeruginosa bacteraemia. Only the ﬁrst bacterae-
mic episode for each patient was included in the
analysis. Community-acquired bacteraemia was
deﬁned as a positive blood culture taken on or
within 48 h of admission. The antimicrobial ther-
apy was considered ‘appropriate’ when the initial
treatment included at least one antibiotic that was
active in vitro against the causative microorgan-
isms, and when the dosage and route of admin-
istration conformed with current medical
standards. As an aminoglycoside was not pre-
scribed in high doses once-daily, which might be
appropriate for P. aeruginosa bacteraemia, amino-
glycoside monotherapy was considered inappro-
priate. The study methods and deﬁnitions were as
described previously [6].
In total, 190 patients with P. aeruginosa bacterae-
mia were identiﬁed, of whom 39 (20.5%) had
community-acquired infection. Among all cases of
community-acquired Gram-negative bacteraemia
(n = 886), 4.4% involved P. aeruginosa. Most (67%)
patients were male, and the mean (± SD) age was
56 ± 14 years (range, 24–95 years). The common-
est underlying diseases were solid tumour (n = 16;
41%) and haematological malignancy (n = 7;
17.9%). Most (44%) patients had neutropenia,
and 38.5% had septic shock at initial presentation.
Overall, 18% of patients had received antibiotics
within the 30 days before the onset of bacteraemia.
The commonest primary sites of infection were
lung (n = 9; 23.1%), pancreaticobiliary tract (n = 8;
20.5%) and the urinary tract (n = 5; 12.8%). No
primary site was identiﬁed for 14 (35.9%) patients.
Two patients who were considered previously
healthy, i.e., with no previous history of hospital-
isation and no known underlying diseases, were
identiﬁed. These patients had pneumonia with
septic shock at the onset of bacteraemia, and died
before the results of microbiological investigations
were available.
The 30-day mortality rate was 38.5%. Of the 15
patients who died as a result of P. aeruginosa
bacteraemia, 13 died within 7 days of hospitali-
sation, and ten within 72 h. The mean time (± SD)
to death was 4.0 ± 5.4 days. The infection-related
attributable mortality rate was 35.9% (14 ⁄ 39). All
patients received antimicrobial therapy, which in
95% of cases was a b-lactam agent with or
without an aminoglycoside. Twenty-four patients,
of whom ten (41.7%) died, received inappropriate
initial antimicrobial therapy, whereas 15 patients,
of whom ﬁve (33.3%) died, received appropriate
initial antimicrobial therapy (p 0.603). Univariate
analysis was performed to assess risk factors for
mortality. Septic shock at initial presentation was
a factor associated signiﬁcantly with mortality
(OR, 71.50; 95% CI, 8.96–570.28; p < 0.001).
Patients with pneumonia had a higher, but not
statistically signiﬁcant, mortality rate (OR, 4.67;
95% CI, 0.95–22.90; p 0.063). Of 39 P. aeruginosa
isolates, only two were resistant to one or more
anti-pseudomonal antibiotics such as ceftazidime,
piperacillin or ciproﬂoxacin. Clinical details of all
patients with community-acquired P. aeruginosa
bacteraemia are summarised in Table 1.
To supplement a previous report focusing on
all cases of P. aeruginosa bacteraemia [6], the
present study focused exclusively on community-
acquired infections over a longer period of time.
Although rare, P. aeruginosa bacteraemia is often
rapidly progressive, and can occur with a high
mortality rate in previously healthy patients [3,4].
P. aeruginosa should be considered in the differ-
ential diagnosis of any patient presenting with
rapidly progressive sepsis, particularly in patients
with pneumonia. The present study conﬁrmed
the adverse prognostic potential of P. aeruginosa in
patients with community-acquired infection.
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When compared with the mortality rate of com-
munity-acquired Klebsiella pneumoniae bacterae-
mia in the same institute during the same period,
the mortality rate of P. aeruginosa bacteraemia was
signiﬁcantly higher (35.9% vs. 16.2%; p 0.002).
Only 38% of patients with P. aeruginosa bacter-
aemia received appropriate initial empirical anti-
biotics. Moreover, as reported previously [6], there
was a signiﬁcant association between survival and
administration of an antimicrobial agent to which
the strain was susceptible in vitro. These data may
explain, at least in part, the high mortality rates
among P. aeruginosa-infected patients. Although
inappropriate initial antimicrobial therapywas not
an independent predictor of death in the present
study, this may simply have been a result of the
small number of cases.
The present data also provide information
regarding the clinical features of patients infected
by P. aeruginosa, which may help to predict
patients who are particularly at risk and to
modify initial empirical antimicrobial therapy.
These data suggest that initial empirical antimi-
crobial cover for P. aeruginosa should be consid-
ered seriously for patients with septic shock at
initial presentation when community-acquired
Table 1. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia
No. Age/Sex
Underlying
diseases
Co-morbid
condition
Septic
shocka
Site of
infectionb
Empirical
antibioticsc
Deﬁnitive
antibiotics Outcome
1 43 ⁄M Lymphoma Corticosteroid use,
neutropenia
Lung CTX, AMK CAZ, AMK, CIP Progression to lung empyema;
died on 50th day of treatment
2 24 ⁄ F Leukaemia Neutropenia Unknown PIP, TOB PIP, TOB Cured
3 55 ⁄M Leukaemia Neutropenia Unknown PIP, TOB PIP, TOB Cured
4 67 ⁄ F Leukaemia Neutropenia Unknown PIP, TOB PIP, TOB Cured
5 62 ⁄M DM Neutropenia Unknown PIP, TOB PIP, TOB Cured
6 48 ⁄M Lymphoma Corticosteroid use,
neutropenia
Yes Unknown PIP, TOB PIP, TOB Died on 1st day of treatment
7 57 ⁄ F Aplastic anaemia Neutropenia Yes Unknown PIP, TOB PIP, TOB Died on 4th day of treatment
8 55 ⁄M Aplastic anaemia Neutropenia Yes Unknown PIP, TOB IPM Died on 9th day of treatment
9 54 ⁄M Leukaemia Central venous
catheterisation,
neutropenia
Unknown CRO, AMK CAZ, AMK Cured
10 66 ⁄M Aplastic anaemia Neutropenia Yes Unknown PIP, TOB PIP, TOB Cured
11 24 ⁄ F Hyperthyroidism Agranulocytosis Eyeball (eyelid) AMS CIP Cured
12 67 ⁄ F Lung cancer Neutropenia Yes Unknown PIP, TOB PIP, TOB Died on 2nd day of treatment
13 61 ⁄M Lung cancer Neutropenia Lung PIP, TOB CAZ, AMK Cured
14 45 ⁄ F Ovarian cancer Neutropenia Unknown PIP, TOB PIP, TOB Cured
15 62 ⁄M Sarcoma Neutropenia Yes Lung CTX, AMK CTX, AMK Died on 1st day of treatment
16 51 ⁄ F ACUP Neutropenia Yes Unknown CTX, AMK, MTZ CTX, AMK Died on 2nd day of treatment
17 52 ⁄M Maxillary cancer Neutropenia Yes Unknown PIP, TOB PIP, TOB Died on 2nd day of treatment
18 33 ⁄M None None Yes Lung CXM, CM CXM, CM Died on 1st day of treatment
19 95 ⁄ F None None Yes Lung CTX, CM CTX, CM Died on 3rd day of treatment
20 63 ⁄M CBD stone None Pancreaticobiliary tract CTX CAZ, AMK Cured
21 59 ⁄ F CBD stone PTBD Pancreaticobiliary tract CTX, AMK, MTZ CTX, AMK, MTZ Cured
22 66 ⁄M IHD stone None Pancreaticobiliary tract CTX, AMK CAZ, AMK Cured after PTBD
23 56 ⁄M CBD stone Prior ERCP Yes Pancreaticobiliary tract CTX, AMK CTX, AMK Died on 5th day of treatment
24 62 ⁄ F Cerebral infarct Neurogenic bladder Urinary tract CIP CIP Cured
25 57 ⁄ F DM None Urinary tract CAZ, AMK CAZ, AMK Cured
26 81 ⁄ F Cerebral infarct Indwelling urinary
catheter
Yes Urinary tract CTX, AMK CTX, AMK Died on 4th day of treatment
27 27 ⁄ F Toxic epidermal
necrolysis
Corticosteroid use Skin CFZ CAZ Cured
28 71 ⁄M ESRD Central venous
catheterisation,
haemodialysis
Catheter-related CFZ, CM CIP Cured with catheter removal
29 65 ⁄M Multiple myeloma Corticosteroid use Yes Unknown CTX CTX Died on 1st day of treatment
30 58 ⁄M Stomach cancer L-tube feeding Yes Lung CTX, AMK CTX, AMK Died on 1st day of treatment
31 41 ⁄M Stomach cancer PTBD Pancreaticobiliary tract CTX CIP Cured with PTBD tube change
32 50 ⁄M Stomach cancer Percutaneous
nephrostomy
Urinary tract CIP CIP Cured
33 56 ⁄M GB cancer None Pancreaticobiliary tract CTX CAZ, AMK Cured with biliary-stent insertion
34 65 ⁄M CBD cancer Prior ERCP Yes Pancreaticobiliary tract CTX, MTZ CAZ, AMK Cured after PTBD
35 51 ⁄M Pancreatic cancer None Pancreaticobiliary tract CTX, MTZ CAZ Cured after PTBD
36 49 ⁄M Lung cancer None Lung CTX CTX Died on 2nd day of treatment
37 51 ⁄M Bladder cancer None Urinary tract CTX CTX Cured
38 69 ⁄M Larynx cancer Tracheostomy Lung CTX, CM CAZ, AMK Cured
39 59 ⁄M Sarcoma None Lung CXM, AZM CAZ, AMK Died on 22nd day of treatment
aSeptic shock at initial presentation.
bThe site of infection was either documented or presumed on the basis of clinical ﬁndings.
cCases 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 17, 24, 25 and 32, who received piperacillin, ceftazidime or ciproﬂoxacin, were considered to have received appropriate empirical
antimicrobial therapy.
DM, diabetes mellitus; ACUP, adenocarcinoma of unknown primary site; CBD, common bile duct; IHD, intrahepatic duct; GB, gall bladder; ERCP, endoscopic retrograde
cholangiopancreaticography; PTBD, percutaneous transhepatic biliary drainage; ESRD, end-stage renal disease; CTX, cefotaxime; CAZ, ceftazidime; CRO, ceftriaxone; CXM,
cefuroxime; CFZ, cefazolin; PIP, piperacillin; AMK, amikacin; TOB, tobramycin; CIP, ciproﬂoxacin; IPM, imipenem; AMS, ampicillin–sulbactam; CM, clindamycin; AZM,
azithromycin.
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Gram-negative bacteraemia is suspected, and
particularly for patients with neutropenia, haem-
atological malignancy or solid tumour, or who
have recently received antibiotics.
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ABSTRACT
This study evaluated the pharmacodynamics of
continuous infusion b-lactams against pulmonary
isolates of Gram-negative bacteria from patients
managed in intensive care units (ICUs) in the
USA. Multiple 10 000-patient Monte Carlo simu-
lations were performed by integrating pharmaco-
kinetic data from healthy individuals with 2408
MICs from the 2002 Intensive Care Unit Surveil-
lance System database. These pharmacodynamic
simulations suggested that continuous infusion
regimens of cefepime, aztreonam, ceftazidime
and piperacillin–tazobactam 13.5 g have the
greatest likelihood of achieving pharmacodynam-
ic targets against isolates of Enterobacteriaceae in
the ICU. b-Lactams are unlikely to achieve phar-
macodynamic targets against Pseudomonas aerugi-
nosa or Acinetobacter baumannii when adminis-
tered as monotherapy.
Keywords Acinetobacter baumannii, b-lactams, Entero-
bacteriaceae, Monte Carlo simulations, pharmacody-
namics, Pseudomonas aeruginosa
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The threat of antibiotic resistance, coupled with a
lack of new antibiotics active against Gram-
negative bacteria in the industrial pipeline, neces-
sitates more effective use of existing therapies.
b-Lactams are one of the most diverse and
clinically useful antibiotic classes, and are active
against a wide array of bacterial species in vitro
[1]. Unfortunately, in-vitro activity alone is not
sufﬁcient to ensure clinical success [2]. Clinical
effectiveness depends on the interplay between
in-vitro activity, pharmacokinetics, host immune
status, tolerability and patient compliance.
In the absence of clinical trial data, pharmaco-
dynamic models satisfy a critical need by
enabling the scientiﬁc community to predict the
likelihood of clinical success based on mathe-
matical models that integrate antimicrobial
susceptibility patterns and antimicrobial pharma-
cokinetics. Animal studies have demonstrated
previously that clinical success is best predicted
by one of three pharmacodynamic indices: the
percentage of time for which the concentration
remains above the MIC (%T > MIC); the ratio of
peak concentration to MIC (Cmax ⁄MIC); and the
ratio of area under the concentration–time curve
to MIC (AUC ⁄MIC) [1]. It has been demonstrated
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